|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4,
493-494 (2006)
DOI: 10.1177/1076029606293837
TGF-ß1 and Endothelial/Tissue Injury With High-dose Intravenous Iron Therapy in Renal Failure: Evidence or Perception?
Joanna Go dzikiewicz, MD
Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bia ystok, Poland
Jacek Borawski, MD
Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bia ystok, Poland
Beata Naumnik, MD
Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bia ystok, Poland
Alicja Rydzewska-Roso owska, MD
Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bia ystok, Poland
Krystyna Pawlak, MD
Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bia ystok, Poland
Micha My liwiec, MD
Department of Nephrology and Transplantology with Dialysis Unit, Medical University, Bia ystok, Poland
References
- Borawski J, Gozdzikiewicz J, Abramowicz P, Naumnik B, Mysliwiec M. Endothelial injury markers with high-dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost 2004; 10: 403-403.[Abstract/Free Full Text]
- Grainger DJ, Mosedale DE, Metcalfe JC. TGF-ßin blood: A complex problem. Cytokine Growth Factor Rev 2000; 11: 133-133.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Saharinen J, Hyytiainen M, Taipale J, Keski-Oja J. Latent transforming growth factor-beta binding proteins (LTBPs)structural extracellular matrix proteins for targeting TGF-beta action. Cytokine Growth Factor Rev 1999; 10: 99-99.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Shah SV, Alam MG. Role of iron in atherosclerosis. Am J Kidney Dis 2003; 41(suppl 1): S80-S80.[ISI][Medline]
[Order article via Infotrieve]
- Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2279.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Grainger DJ. Transforming growth factor-ßand atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399-399.[Abstract/Free Full Text]
- Junker U, Haufe CC, Nuske K, et al. Elevated plasma TGF-ß1 in renal diseases: Cause or consequence? Cytokine 2000; 12: 1084-1084.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Harris H, Kirschenlohr H, Szabados N, Metcalfe J. Transforming growth factor-ß1 inhibits thrombin activation of endothelial cells. Cytokine 2004; 25: 85-85.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Stefoni S, Cianciolo G, Donati G, et al. Low TGF-ß1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002; 61: 324-324.[CrossRef][ISI][Medline]
[Order article via Infotrieve]

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
|